GP (33-41)
GP (33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM[1].
Product Specifications
CAS Number
161928-86-5
UNSPSC
12352209
Target
Arenavirus
Type
Peptides
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/GP_33-41_.html
Solubility
10 mM in H2O
Smiles
O=C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(O)=O)=O)=O)=O)CC1=CC=CC=C1)=O)[C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@@H](N)CCCCN)=O)=O)=O)CC(C=C2)=CC=C2O
Molecular Formula
C46H69N11O13S
Molecular Weight
1016.17
References & Citations
[1]Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69 (4) :2297-305.|[2]Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37 (3) :798-806.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog